Regenerative medicine for musculoskeletal pain is shifting from temporary symptom relief to tissue restoration using Polydeoxyribonucleotide (PDRN), Atelocollagen, and Platelet-Rich Plasma (PRP). According to clinical data presented at the ‘2026 GC녹십자웰빙 통증 좌담회’, these therapies target inflammation and cellular repair to treat knee osteoarthritis, rotator cuff tears, and chronic tendonitis, offering alternatives to corticosteroids for high-risk patients.
PDRN and Atelocollagen: Shifting the Joint Injection Paradigm
Clinical practice is moving away from simple pain masking toward inducing tissue regeneration. Polydeoxyribonucleotide (PDRN), a low-molecular-weight DNA fraction derived from salmon or trout, utilizes a dual mechanism of inducing angiogenesis and activating the DNA salvage pathway to reduce inflammation and repair tissue. Atelocollagen, derived from Type I collagen with telopeptides removed to lower immunogenicity, acts as a physical scaffold that promotes fibroblast attachment and collagen rearrangement in tendons and ligaments.
Evidence for these agents includes:
- Knee Osteoarthritis (KOA): A 2019 study published in J Pain Res and a corresponding meta-analysis in Medicine found that combining PDRN with Hyaluronic Acid (HA) yielded significant improvements in pain and function compared to HA alone. Furthermore, a 2024 study in Cureus reported significant pain reduction in 96.7% of KOA patients treated with Atelocollagen.
- Shoulder and Rotator Cuff: PDRN injections in the shoulder joint showed pain relief comparable to triamcinolone, providing a safer option for patients with diabetes or metabolic syndrome who cannot tolerate steroids. Research in CISE (2025) noted that a single 3 mL PDRN injection mixed with 1% lidocaine reduced pain and analgesic use in rotator cuff tear patients.
- Tendonitis and Plantar Fasciitis: PDRN has shown efficacy in treating lateral epicondylitis and plantar fasciitis, with a 2024 Preprints.org study indicating that combining PDRN with exercise therapy accelerates functional recovery.
Platelet-Rich Plasma (PRP) Concentration and Efficacy
Platelet-Rich Plasma (PRP) utilizes concentrated growth factors from a patient’s own blood to regenerate damaged nerves and blood vessels. Recent data indicates that the concentration of platelets is the primary driver of success. A 2025 meta-analysis in the Am J Sports Med concluded that high-concentration PRP results in lower treatment failure rates and superior functional improvement compared to low-concentration versions.
According to clinical reports from the symposium, leukocyte-rich PRP is frequently used for its strong tissue regeneration response. Success rates increase significantly when platelet counts exceed 1,200,000 platelets/mL. The Dr. PRP kit, which holds FDA certification, uses a double-spin centrifugation technique to increase platelet concentration 2-3 times while removing unnecessary leukocytes to minimize inflammatory reactions.
Current application standards for PRP include:
- Bridging Therapy: Used for short-term pain relief after ACL reconstruction or as a bridge for end-stage arthritis patients awaiting total joint replacement.
Dried Bee Venom and Hyaluronidase for Chronic Pain
Dried bee venom (Apitoxin) is a quantified pharmaceutical containing peptides such as melittin and apamin. Unlike steroids, which often see symptom recurrence within months, bee venom is reported to suppress pain recurrence for several years due to its potent immunomodulatory effects. Melittin reduces the secretion of inflammatory cytokines, while Phospholipase A2 (PLA2) provides neuroprotective effects and reduces autoimmune responses, according to a 2020 study in Toxins (Basel).
To manage the risk of anaphylaxis, clinicians perform skin reaction tests and maintain epinephrine on-site. For severe spinal stenosis or chronic myofascial pain syndrome, combining bee venom with Berahyaluronidase alfa (Terga-ze) can increase drug permeability by 20-30% by expanding the diffusion range within the tissue.
Comparative Summary of Regenerative Options
| Therapy | Primary Mechanism | Best Use Case | Key Advantage |
|---|---|---|---|
| PDRN | DNA Salvage/Angiogenesis | Tendonitis, Early KOA | Steroid alternative for diabetics |
| Atelocollagen | Structural Scaffolding | Ligament/Tendon Repair | Low immunogenicity, slow degradation |
| PRP | Growth Factor Signaling | Severe Tears, Late-stage KOA | Autologous (patient’s own blood) |
| Bee Venom | Immune Modulation | Chronic Myofascial Pain | Long-term recurrence suppression |
The integration of these therapies allows for a tiered approach to pain management. Clinicians may start with PDRN as a bridge to more intensive treatments, moving to PRP for patients who do not respond to initial regenerative injections. The expansion of these tools provides a viable pathway for aging populations and patients with comorbidities who require long-term musculoskeletal stability without the systemic risks of chronic steroid use.
Worth a look